Literature DB >> 24016673

Stereotactic body radiotherapy (SBRT) in central non-small cell lung cancer (NSCLC): solid evidence or "no-go"?

Ursula Nestle1, Corinne Faivre-Finn, Dirk DeRuysscher, Coen Hurkmans, Matthias Guckenberger, Jose Belderbos, Cecile le Pechoux.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24016673     DOI： 10.1016/j.radonc.2013.07.022

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


× No keyword cloud information.
  3 in total

1.  Cons: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?

Authors:  Ursula Nestle; José Belderbos
Journal:  Transl Lung Cancer Res       Date:  2015-10

2.  Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis.

Authors:  Daniel H Schanne; Ursula Nestle; Michael Allgäuer; Nicolaus Andratschke; Steffen Appold; Ute Dieckmann; Iris Ernst; Ute Ganswindt; Anca L Grosu; Richard Holy; Michael Molls; Meinhard Nevinny-Stickel; Sabine Semrau; Florian Sterzing; Andrea Wittig; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2014-08-27       Impact factor: 3.621

3.  SBRT for centrally localized NSCLC - What is too central?

Authors:  J Roesch; C Panje; F Sterzing; F Mantel; U Nestle; N Andratschke; M Guckenberger
Journal:  Radiat Oncol       Date:  2016-12-03       Impact factor: 3.481
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.